RB
Rajendra Baliramji Kakde
About Rajendra Baliramji Kakde
Data last updated:
Rajendra Baliramji Kakde is a Director at 72 Nagpur Pharma Con Foundation (since 2024). The company operates in Software. 72 Nagpur Pharma Con Foundation reported revenue of ₹12,600 (FY 2024).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
 72 Nagpur Pharma Con Foundation U72200MH2023NPL407421 | Director | 30 Dec 2024 | 2023 | ₹12,600 (FY 2024) | Active |
Board colleagues of Rajendra Baliramji Kakde
| Name | DIN | Company | Designation |
|---|---|---|---|
| Atul Vijay Mandlekar | 10254967 | 72 Nagpur Pharma Con Foundation | Director |
| Chandrashekhar Appasaheb Doifode | 10881168 | 72 Nagpur Pharma Con Foundation | Director |
| Nishikant Ambadas Raut | 10254968 | 72 Nagpur Pharma Con Foundation | Director |
| Prakash Rambhau Itankar | 10881172 | 72 Nagpur Pharma Con Foundation | Director |
| Pushpahas Mukund Ballal | 10254966 | 72 Nagpur Pharma Con Foundation | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Rajendra Baliramji Kakde
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Rajendra Baliramji Kakde
Rajendra Baliramji Kakde currently holds 1 directorship: 72 Nagpur Pharma Con Foundation (Director, since 30 Dec 2024, revenue ₹12,600 (FY 2024)).
Rajendra Baliramji Kakde was first appointed on 30 Dec 2024 as Director at 72 Nagpur Pharma Con Foundation.
The current boards of Rajendra Baliramji Kakde's companies include Atul Vijay Mandlekar (72 Nagpur Pharma Con Foundation), Chandrashekhar Appasaheb Doifode (72 Nagpur Pharma Con Foundation), Nishikant Ambadas Raut (72 Nagpur Pharma Con Foundation), Prakash Rambhau Itankar (72 Nagpur Pharma Con Foundation), Pushpahas Mukund Ballal (72 Nagpur Pharma Con Foundation).